# Ganciclovir to Prevent Reactivation of Cytomegalovirus in Patients With Acute Respiratory Failure and Sepsis

> **NCT04706507** · PHASE3 · TERMINATED · sponsor: **Fred Hutchinson Cancer Center** · enrollment: 205 (actual)

## Conditions studied

- Acute Respiratory Failure

## Interventions

- **DRUG:** IV Ganciclovir
- **DRUG:** Normal saline

## Key facts

- **NCT ID:** NCT04706507
- **Lead sponsor:** Fred Hutchinson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-06-29
- **Primary completion:** 2024-10-25
- **Final completion:** 2025-04-08
- **Target enrollment:** 205 (ACTUAL)
- **Why stopped:** due to increased mortality and futility analyses
- **Last updated:** 2025-12-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04706507

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04706507, "Ganciclovir to Prevent Reactivation of Cytomegalovirus in Patients With Acute Respiratory Failure and Sepsis". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04706507. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*